Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Skin Neoplasms 7Neoplasm Metastasis 6Squamous Cell Carcinoma of Head and Neck 5Melanoma 5Lung Neoplasms 5Carcinoma 5Recurrence 4Neoplasms 4Colorectal Neoplasms 4Mouth Neoplasms 3Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Adenocarcinoma 3Ovarian Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Basal Cell 2Vaccinia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Bevacizumab 39atezolizumab 26durvalumab 24Nivolumab 21lenvatinib 20tremelimumab 16Specimen Handling 16Magnetic Resonance Spectroscopy 13sintilimab 11pembrolizumab 11Ipilimumab 10tislelizumab 7X-Rays 7Sorafenib 7Immunoglobulin G 7regorafenib 6Disulfides 6Cyclophosphamide 6cabozantinib 5Radiotherapy 5Radiosurgery 5Blood Specimen Collection 5Radiation 4Oxaliplatin 4Immunotherapy 4Fluorouracil 4Ethiodized Oil 4Biopsy 4fludarabine 3donafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × cemiplimab × 90 days × Clear all
NCT03916627 2026-04-06

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
65 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡